A fast-growing cancer drug. Blockbuster vaccines. Significant challenges.All three of these apply to Pfizer (NYSE: PFE), but they also all apply to Merck (NYSE: MRK). Both pharmaceutical companies have successful products with sizzling sales, but both have experienced headwinds that have weighed on their overall revenue and earnings growth. Which of these big pharma stocks is the better pick for long-term investors?